Natura (B3: NATU3), the iconic Brazilian beauty giant and parent of the Natura and Avon brands across Latin America, reported a Q1 2026 net loss of R$445 million ($88 million) — nearly triple the R$152 million ($30 million) loss reported in the same period of 2025, according to the earnings release published Monday May 11.
Net revenue fell 7.7 percent year-on-year to R$4.75 billion ($941 million), and recurring EBITDA collapsed 55.7 percent to R$346 million ($69 million). The result missed the LSEG analyst consensus of R$430 million ($85 million) EBITDA on R$4.3 billion ($852 million) revenue by approximately 20 percent, per data tracked by LSEG.
Shares of NATU3 fell 5.62 percent on Tuesday to close near R$9.99 ($1.98), making Natura the single largest decliner on the Ibovespa for the session. The stock had previously been one of the year’s strongest performers — up roughly 50 percent year-to-date heading into the print, per data tracked by Money Times — but the magnitude of the miss reset positioning sharply.
The EBITDA margin compressed to 7.3 percent from 14.7 percent in Q1 2025 — a 740-basis-point deterioration. Management framed the quarter as “transitional,” pressured by weak Brazilian consumer demand, the slow post-integration recovery in Argentina, and the timing of the Avon brand relaunch which only began in March.
Key Points
What Natura Reported in Q1 2026
Natura Cosméticos — listed on B3 as NATU3 — is one of Brazil’s most globally recognised brands and the largest cosmetics and direct-selling group in Latin America. The company operates the Natura and Avon brands across more than 70 countries through approximately 6 million consultants and representatives, with strategic markets in Brazil, Mexico, Argentina, Colombia, Peru and Chile.
Q1 2026 net loss reached R$445 million ($88 million), nearly triple the R$152 million ($30 million) loss reported in Q1 2025. Including the discontinued operations effect, the loss represented a 787.6 percent year-on-year increase versus the R$50 million ($10 million) Q1 2025 loss attributable to continuing operations only.
Net revenue declined 7.7 percent year-on-year to R$4.75 billion ($941 million), missing the R$4.3 billion ($852 million) LSEG analyst consensus. Brazil revenue fell 5.5 percent in the quarter, of which approximately 3 percentage points came from the core Natura brand and 13.8 percentage points from Avon — a substantial divergence that highlights the depth of the Avon transition challenge.
Recurring EBITDA was R$346 million ($69 million), down 55.7 percent year-on-year and approximately 20 percent below the R$430 million ($85 million) LSEG analyst consensus. The EBITDA margin compressed to 7.3 percent from 14.7 percent in Q1 2025 — a 740-basis-point deterioration that XP Investimentos attributed to below-expected gross margin, operating deleverage and severance expenses tied to the company’s restructuring.
Excluding non-recurring items related to layoffs, BTG Pactual calculated the underlying net loss at approximately R$224 million ($44 million) — still a meaningful operational deterioration. Hedge losses tied to the company’s US-dollar-denominated debt added pressure to the bottom line in the quarter, per the BTG Pactual analysis.
Free cash flow to the firm was burned at approximately R$430 million ($85 million) in Q1, driven by R$330 million ($65 million) of extraordinary cash costs related to the implementation of the new operating model and to the Chapman settlement agreement, per XP Investimentos. Excluding those one-off items, free cash flow was approximately neutral, per management commentary.
CEO João Paulo Ferreira characterised the period as “a challenging quarter, both in revenue and profitability, although aligned with our expectations” in the press conference following the release. The framing matters: the magnitude of the miss versus LSEG consensus suggests sell-side expectations were higher than internal management forecasts.
Despite the headline weakness, Natura gained market share in Brazil during the quarter through what management called “sell-out growth” — sales to end consumers — and sequential growth in the relationship-selling channel. Digital sales in Brazil grew 23.6 percent year-on-year and retail revenue grew 14.3 percent. The Natura brand grew 7 percent in constant currency across Hispanic markets excluding Argentina.
The Northeast region of Brazil was the principal operational drag domestically. Lower consumer disposable income — pressured by elevated household indebtedness and the persistent 15 percent Selic environment — has compressed beauty-and-personal-care spending in a region that historically over-indexes for Natura’s direct-selling channel.
Temporary operational disruptions added to the Q1 challenge. The closure of the Interlagos factory in São Paulo and the implementation of a new integrated planning system caused service-level disruptions during the quarter. These disruptions impacted the relationship-selling channel productivity and reduced consultant activity.
The consultant base — the foundation of Natura’s direct-selling model — has been contracting. The company has a smaller and less active network than a year earlier, with lower productivity per consultant particularly among those at the lower-volume end of the distribution. Rebuilding consultant engagement is the most important operational priority for the remainder of 2026.
Argentina remained a structural challenge. The post-Avon integration recovery is occurring more slowly than originally expected, compounded by declining domestic consumption and unfavourable currency movements. Across Hispanic markets excluding Argentina, Natura delivered solid performance — proving the integration model works when macro conditions cooperate.
Live Company IntelligenceNATU3 — the full investor dossier
Why Natura Q1 Matters
Natura is one of Brazil’s most globally recognised consumer brands and the listed proxy for the Latin American beauty and direct-selling sector. The 5.62 percent stock decline on Tuesday made NATU3 the single largest single-name move on the Ibovespa for the session — significant because the index itself fell only 1.2 percent, meaning Natura accounted for a disproportionate share of the day’s wealth destruction.
The miss is a setback to a turnaround narrative that had been gathering momentum. NATU3 was up approximately 50 percent year-to-date heading into the Q1 print, with J.P. Morgan having recently upgraded the stock to Buy. The Q1 result triggered a sharp positioning reset, with the stock falling to within a few cents of XP Investimentos’ Advent-bid valuation floor of R$9.75 ($1.93) per share.
The strategic context is critical. Natura has spent the last three years executing a “shrink to grow” strategy — divesting Aesop to L’Oréal for $2.53 billion in 2023, selling The Body Shop for approximately R$1.2 billion ($238 million), and most recently, selling Avon International to US private equity firm Regent for a nominal £1 in September 2025. The company is now a focused Latin American beauty group, no longer a global beauty conglomerate.
As the Rio Times reported in October 2025, Natura subsequently folded Avon Industrial — the Brazilian manufacturing unit — directly into the parent, closing the legacy Interlagos plant in São Paulo and concentrating production at Cajamar. The Q1 disruption tied to the Interlagos closure and new planning system implementation is the direct cost of that strategic reorganisation finally landing in the P&L.
The Avon relaunch is the central operational catalyst. The new Avon positioning launched in Brazil and Mexico in March 2026 with a refreshed innovation portfolio. Early sales are running above expectations, per CEO Ferreira, but the rollout is too recent to lift Q1 numbers. The full effect should appear in Q2 and Q3 — which is why analysts including BTG Pactual and Itaú BBA frame the Q3 print as the inflection point for the recovery thesis.
The path to validation is narrow. Itaú BBA reiterated Outperform with a R$14 ($2.77) price target, expecting Brazilian operations to accelerate to mid-single-digit revenue growth by Q3. XP Investimentos took a more cautious stance, expecting investors to return to a wait-and-see posture given heightened macro and execution risks. BTG Pactual noted that “after successfully navigating structural challenges including the Avon International divestiture, an effective re-rating now depends on execution — and the Q1 results do not yet address these uncertainties.”
For foreign investors, Natura’s story is the cleanest case study in Brazil of how the post-pandemic global beauty M&A wave has unwound. The 2020 Avon acquisition created the world’s fourth-largest beauty group on paper. The pandemic, post-pandemic inflation and 2023-2024 financial crisis exposed the integration challenges, forcing the Aesop, Body Shop, and Avon International disposals.
As the Rio Times reported in February 2025, the strategic simplification has now culminated in a focused Latin American group — but the road from disposal to organic recovery is now where Natura must execute.
The contrast with Q4 2024 is instructive. That print produced a 27.5 percent single-day stock collapse on a negative R$139.6 million ($28 million) EBITDA driven by Avon International reconsolidation accounting noise. The Q1 2026 miss is structurally cleaner — there are no Chapter 11 accounting distortions — but the operational miss is more meaningful precisely because the balance sheet and corporate structure are now simplified.
The competitive landscape in Brazilian beauty remains intense. Boticário Group is the largest privately held competitor, while in the listed space, Hypera (HYPE3) covers pharma-adjacent personal care and Vivara (VIVA3) operates in jewellery-adjacent luxury. Natura’s premium positioning under the Natura brand — alongside the mass-market Avon repositioning — gives the company a dual-channel strategy that few peers match.
Digital and retail growth remained strong even as direct-selling slipped. Digital sales in Brazil grew 23.6 percent year-on-year and retail revenue grew 14.3 percent. The trend supports the case for omni-channel transition — but the direct-selling channel is still the cornerstone of the model, and consultant productivity decline is the most important leading indicator to monitor.
Natura held its dollar-denominated debt hedging discipline through the quarter. The financial result was nevertheless negatively affected by hedge losses on the dollar debt — a structural reminder that even a Latin American-focused company is exposed to currency volatility through its remaining international borrowings.
For Brazilian and expat consumers, Natura remains the most recognisable Brazilian beauty brand globally. Brand Finance has previously named Natura “the strongest brand in the world” in the cosmetics sector. The market-share gain in Brazil during Q1 — through sell-out growth despite the consultant-base contraction — suggests the brand equity remains intact. The execution challenge is operational, not brand-related.
Natura Q1 2026 Financial Snapshot
| Indicator | Q1 2026 | Chg YoY |
|---|---|---|
| Net Loss | -R$445M ($88M) | vs -R$152M ($30M) |
| Net Revenue | R$4.75B ($941M) | -7.7% |
| Recurring EBITDA | R$346M ($69M) | -55.7% (miss ~20%) |
| EBITDA Margin | 7.3% | -740 bps (vs 14.7%) |
| FCF (ex-extraordinary) | ~Neutral | Excl. R$330M ($65M) costs |
| Underlying Net Loss (ex-non-recurring) | -R$224M ($44M) | Per BTG Pactual estimate |
Regional and Channel Performance
| Metric | Q1 2026 | Comment |
|---|---|---|
| Brazil Revenue | -5.5% YoY | Natura -3%, Avon -13.8% |
| Brazil Digital Sales | +23.6% YoY | Omni-channel growth |
| Brazil Retail Revenue | +14.3% YoY | Brand stores expanding |
| Natura Brand (Hispanic ex-Arg) | +7% (constant FX) | Mexico recovery |
| Argentina | Pressured | Slow post-Avon recovery |
| NATU3 Stock Reaction | -5.62% on May 12 | Largest Ibovespa decliner |
What Happens Next for Natura
Q3 inflection test: Analyst consensus — including Itaú BBA, BTG Pactual and XP — frames Q3 as the moment Brazil’s operations should accelerate to mid-single-digit revenue growth, validating the recovery thesis. Anything weaker would extend the wait-and-see positioning that XP has flagged.
Avon relaunch performance: The March 2026 Avon relaunch in Brazil and Mexico is showing early sales above expectations, per management. Q2 and Q3 numbers need to validate the trajectory. If Avon Brazil moves from -13.8% to growth, the consolidated revenue trajectory reverses.
Consultant base rebuild: Lower headcount and reduced consultant productivity are the most concerning leading indicators. Recovery in the direct-selling channel is the structural priority — digital and retail growth alone cannot offset direct-selling erosion at scale.
Argentina recovery timing: The post-Avon-integration recovery in Argentina is happening more slowly than originally forecast. Watch for whether Q2 brings stabilisation, or whether the macro environment continues to compress beauty demand in a structurally important Hispanic market.
Advent bid floor: Per XP Investimentos analysis, Advent’s non-binding indicative offer at R$9.75 ($1.93) per share provides a price floor for NATU3 — the stock closed near that level on the post-results decline. Continued underperformance would test whether the bid stays in place.
Frequently Asked Questions
How much did Natura lose in Q1 2026?
Natura reported a Q1 2026 net loss of R$445 million ($88 million), nearly triple the R$152 million ($30 million) loss reported in the same period of 2025. Net revenue fell 7.7 percent year-on-year to R$4.75 billion ($941 million), and recurring EBITDA collapsed 55.7 percent to R$346 million ($69 million).
The result missed the LSEG analyst consensus of R$430 million ($85 million) EBITDA on R$4.3 billion ($852 million) revenue by approximately 20 percent. The EBITDA margin compressed to 7.3 percent from 14.7 percent in Q1 2025, a 740-basis-point deterioration tied to weak Brazilian consumer demand, slow Argentina recovery, and restructuring-related extraordinary costs of R$330 million ($65 million).
Why did Natura stock fall 5.6%?
NATU3 fell 5.62 percent on Tuesday May 12 to close near R$9.99 ($1.98), making Natura the single largest decliner on the Ibovespa for the session. The magnitude of the miss versus the LSEG analyst consensus — approximately 20 percent on EBITDA — triggered a sharp positioning reset.
The stock had been up approximately 50 percent year-to-date heading into the print and had recently been upgraded to Buy by J.P. Morgan. The Q1 weakness extended a multi-quarter pattern of execution challenges and pushed the share price to within a few cents of XP Investimentos’ R$9.75 ($1.93) Advent-bid valuation floor.
What is the Avon relaunch?
In March 2026, Natura began relaunching the Avon brand in Brazil and Mexico with new positioning and a refreshed innovation portfolio. The relaunch follows three years of strategic simplification that included the divestiture of Aesop to L’Oréal for $2.53 billion in 2023, the sale of The Body Shop for approximately R$1.2 billion ($238 million), and the sale of Avon International to US private equity firm Regent for a nominal £1 in September 2025.
Early sales from the relaunch are running above expectations, per CEO João Paulo Ferreira, but the rollout is too recent to materially lift Q1 numbers. Analysts including BTG Pactual and Itaú BBA expect the impact to appear in Q2 and Q3 results, framing Q3 as the inflection point for the recovery thesis.
What is the outlook for Natura shares?
Sell-side coverage is divided. Itaú BBA reiterated Outperform with a R$14 ($2.77) price target, expecting Brazilian operations to accelerate to mid-single-digit revenue growth by Q3. J.P. Morgan upgraded to Buy earlier in 2026. XP Investimentos took a more cautious stance, expecting investors to return to a wait-and-see posture given heightened macro and execution risks.
BTG Pactual noted that an effective re-rating depends on execution of growth drivers and margin-recovery trends — and that the Q1 results do not yet address these uncertainties. Advent’s non-binding indicative offer at R$9.75 ($1.93) per share provides a price floor that limits downside, but the path to sustained re-rating requires the Q2 and Q3 prints to confirm the recovery thesis is intact.
Updated: 2026-05-13T07:30:00-03:00 by Rio Times Editorial Desk
Natura Q1 2026 | NATU3 earnings | Brazil cosmetics | João Paulo Ferreira | Avon relaunch | Argentina recovery | Ibovespa losers | The Rio Times
Read More from The Rio Times